Chemotherapy Initiation in Elderly Men with Metastatic Prostate Cancer

Initial Treatment Considerations

For elderly men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) with widespread bone metastases, chemotherapy with docetaxel should be started immediately at diagnosis alongside androgen deprivation therapy (ADT) if the patient is fit enough to tolerate it, as recommended by the European Society for Medical Oncology 1, 2, 3
The American Society of Clinical Oncology suggests that fit elderly patients should receive the same aggressive treatment as younger patients, considering health status rather than chronological age alone 5
Life expectancy estimation should use validated tools, showing a significant difference in life expectancy between the healthiest and unhealthiest quartiles, with a 65-year-old in the healthiest quartile having a 24-year life expectancy versus 8 years in the unhealthiest quartile 5

The European Association of Urology recommends ADT + docetaxel + abiraterone + prednisone (triplet therapy) as first-line treatment for fit men with de novo mHSPC, especially those with multiple bone metastases (>3) or visceral metastases 2
ADT + docetaxel alone is recommended as first-line treatment for metastatic hormone-naïve disease in men fit enough for chemotherapy, with a docetaxel dose of 75 mg/m² every 3 weeks for 6 cycles, administered with prednisone 5 mg orally twice daily 1, 3
For older or unhealthier patients, ADT alone or ADT + novel hormonal agent (without chemotherapy) should be considered, as suggested by the National Comprehensive Cancer Network 6, 2

The European Society for Medical Oncology recommends hematologic monitoring, with growth factor support (G-CSF) considered in patients ≥65 years to decrease neutropenic complications 4
Bone health monitoring is crucial, with increased fracture risk in elderly patients receiving ADT, and consideration of denosumab, zoledronic acid, or alendronate for high fracture risk 4, 5
PSA and clinical monitoring should be performed every 3 months during year 1, then every 6 months, with digital rectal examination at follow-up visits and bone scan and imaging if PSA rises or symptoms develop 4, 5

Relative contraindications for upfront chemotherapy include severe comorbidities limiting life expectancy to <2 years, poor performance status, or dependence in activities of daily living, as noted by the American Society of Clinical Oncology 2, 5
Withholding chemotherapy based solely on age is a common pitfall, as evidence shows healthy elderly adults have similar treatment outcomes to younger counterparts 5
Waiting for castration-resistant disease to develop before starting chemotherapy is another pitfall, as the strongest evidence supports upfront chemotherapy with ADT in the hormone-sensitive phase 1, 2, 3